Orally effective methylphenidate extended release powder and aqueous suspension product
AssigneeTris Pharma, Inc.
InventorsKetan Mehta, Yu-Hsing Tu, Ashok Perumal
Life of this patent
Estimating the term…
Loading patent…
AssigneeTris Pharma, Inc.
InventorsKetan Mehta, Yu-Hsing Tu, Ashok Perumal
Estimating the term…
An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile.
A methylphenidate aqueous extended release oral suspension comprising (1) an immediate release methylphenidate component, (2) a sustained release methylphenidate component comprising a water-insoluble, water-permeable, pH-independent, barrier coated methylphenidate-ion exchange resin complex, and (3) water,
A methylphenidate extended release powder blend, said extended release powder blend comprising:
Dependencies are inferred from the claim text.